论文部分内容阅读
目的观察超声引导下射频消融(RFA)治疗原发性肝癌的疗效及安全性。方法 2007年12月—2012年12月我科应用超声引导下RFA治疗具有明确病理诊断的原发性肝癌36例,采用RECIST实体瘤评价标准进行疗效评估,依据NCI-CTC 3.0标准评估不良反应发生情况。结果本组总有效率为80.6%。Ⅲ~Ⅳ度不良反应发生率为16.7%,经对症治疗后缓解。结论原发性肝癌行超声引导下RFA疗效显著且安全性较好。
Objective To observe the efficacy and safety of ultrasound-guided radiofrequency ablation (RFA) in the treatment of primary liver cancer. Methods From December 2007 to December 2012, 36 cases of primary hepatocellular carcinoma with definite pathological diagnosis underwent ultrasound guided RFA. We evaluated the efficacy of the RECIST solid tumor evaluation criteria and evaluated the adverse reactions according to the NCI-CTC 3.0 standard Happening. Results The total effective rate was 80.6%. Ⅲ ~ Ⅳ degrees of adverse reactions was 16.7%, after symptomatic treatment to ease. Conclusion The ultrasound-guided RFA of primary liver cancer has obvious curative effect and good safety.